This is a case report of a 36-year-old male who was diagnosed with acute inferior and right ventricular myocardial infarction and treated with percutaneous coronary angioplasty with a drug-eluting stent in the right coronary artery. A profile test for thrombophilia was performed for methylene tetrahydrofolate reductase (MTHFR) gene mutation; the test was positive for a heterozygous mutation -C677C and 1298A. The patient received a long-term treatment with folic acid supplements, taken daily. This case report shows that medical doctors should have an outside-the-box approach for the diagnosis and therapeutic management of young patients who present with acute cardiovascular events. If the patient in question does not present clear cardiovascular risk factors for acute myocardial ischemia, the clinician should seek for possible causes, thus leading to several benefits in the management and secondary prevention of such cases.
InTROduCTIOn
Adjustable risk factors for ischemic heart disease consist of elevated arterial blood pressure, hyperlipidemia, chronic tobacco use, increased body weight, sedentary lifestyle, diabetes mellitus, and anxiety. 1 Other aspects, such as gender and age, are unchangeable cardiovascular risk factors. 2 If a patient is admitted to the hospital for typical symptoms of an acute thrombotic event (acute myocardial infarction in the presented case), without any significant cardiovascular risk factors, the clinician is required to exclude genetic disorders as etiology for the acute diagnosis. 3 Genetic causes that have been shown to be independent risk factors for acute thrombotic events include the mutation of several genes that encode the coagulation factors, such as antithrombin, C and S protein, fibrinogen, prothrombin, and factor V from the clotting cascade. 4 The genetic mutation of the methylene tetrahydrofolate reductase (MTHFR) gene, which causes a transitional shift in cytosine to thymidine on the 677 nucleotide, leads to a low enzymatic activity and a modified folic acid state with increased folate necessity. The 677 T mutation of the gene that encodes the MTHFR causes C/C, C/T, and T/T genotypes, leading to an elevated serum level of homocysteine in human subjects. 5, 6 Increased levels of homocysteinemia lead to early atherosclerotic lesion formation and venous thromboembolism. 
CASE PRESEnTATIOn
The patient, male, 36 years old, presented to the Emergency The patient agreed to the publication of his data and the institution where the patient had been admitted approved the publication of the case.
dISCuSSIOn
Coronary atherosclerotic lesions appear as a result of a complex process that takes place within the vessel wall.
Several studies have evaluated the involvement of homocysteine in the process of cell injury at the level of the endothelium. 8, 9 Genetic polymorphism associated with several risk factors leads to increased incidence of ischemic heart disease.
Elevated serum levels of homocysteine, caused by MTHFR gene mutation, can be treated with folate supplements. It has been shown that the clinical evolution of arterial or venous thrombotic events in patients with MTHFR gene mutation and increased homocysteine levels improves under supplementation with folic acid, as seen also in this case report. 10 Gene disorders that affect clotting factor V, prothrombin, and homocysteine, increase the risk of developing acute coronary syndromes or stroke, especially at a young age. 11 Nevertheless, the screening protocol applies to a relatively low number of subjects, since the number of In the case presented here, screening for MTHFR gene mutation was performed due to the patient's age and lack of cardiovascular risk factors.
We found few cases with acute MI and MTHFR gene mutation in the literature. The first report was published in 1997, on a 35-year-old male patient who presented with acute MI, a homozygous MTHFR gene mutation that led to hyperhomocysteinemia, and a heterozygous mutation of the Leiden V factor gene. 13 The patient also presented several risk factors for ischemic heart disease, including late onset type I diabetes and increased cholesterol level.
The other described cases also presented a homozygote 
COnCLuSIOnS
When the presentation diagnosis is not explained by established pathophysiological mechanisms and there are no obvious and identifiable etiological explanations, clinicians should seek for rare causes that will eventually lead to a complex therapeutic approach, beneficial for both the patients and their families.
